Front Immunol. 2018 Feb 9;9:193. [IF: 6.4]. Reinforcing the functionality of mononuclear phagocyte system to control tuberculosis. Pahari S, Kaur G, Negi S, Aqdas M, Das DK, Bashir H, Singh S, Nagare M, Khan J, Agrewala JN.
Front Immunol. 8:2017:624 [IF: 6.4]. Diametric role of the latency-associated protein acr1 of mycobacterium tuberculosis in modulating the functionality of pre and post maturational stages of dendritic cells. Amir M, Aqdas M, Nadeem S, Siddiqui KS, Khan N, Sheikh JS, Agrewala JN.
Front Immunol. 8:2017:906 [IF: 6.4]. Bolstering immunity through pattern recognition receptors: a unique approach to control tuberculosis. Pahari S, Kaur G, Aqdas M, Negi S, Chatterjee D, Bashir H, Singh S, Agrewala JN.
Crit Rev Microbiol. 1:2016:1 [IF: 8.2]. T cell exhaustion in tuberculosis: pitfalls and prospects. Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala JN.
Front Immunol. 7:2016:529 [IF: 6.4]. Alteration in the gut microbiota provokes susceptibility to tuberculosis. Khan N, Vidyarthi A, Nadeem S, Negi S, Nair G, Agrewala JN.
Scientific Reports. 6:2016:39492. [IF: 5.6]. Infergen stimulated macrophages restrict Mycobacterium tuberculosis growth by autophagy and release of nitric oxide. Pahari S, Khan N, Aqdas M, Negi S, Kaur J, Agrewala JN.
Front Immunol. 7:2016:386 [IF: 6.4]. Stimulation through CD40 and TLR-4 is an effective host directed therapy against Mycobacterium tuberculosis. Khan N, Pahari S, Vidyarthi A, Aqdas M, Agrewala JN.
Scientific Reports. 6:2016:27263 [IF: 5.6]. Triggering through NOD-2 Differentiates Bone Marrow Precursors to Dendritic Cells with Potent Bactericidal activity. Khan N, Aqdas M, Vidyarthi A, Negi S, Pahari S, Agnihotri T, Agrewala JN.
Scientific Reports. 6:2016:23917 [IF: 5.6]. A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host. Rai PK, Chodisetti SB, Nadeem S, Maurya SK, Gowthaman U, Zeng W, Janmeja AK, Jackson DC, Agrewala JN.
Scientific Reports 6:2016:19084 [IF: 5.6]. Signaling through NOD-2 and TLR-4 Bolsters the T cell priming capability of dendritic cells by inducing autophagy. Khan N, Vidyarthi A, Pahari S, Negi S, Aqdas M, Nadeem S, Agnihotri T, Agrewala JN.
Crit Rev Microbiol. 4:2015:389 [IF: 8.192]. Challenges and Solutions for a Rational Vaccine Design for TB-endemic Regions. Gowthaman U, Mushtaq K, Tan AC, Rai PK, Jackson DC, Agrewala JN.
J Infect Dis. 211:2015: 486-96 [IF: 6.3]. Triggering through TLR-2 limits chronically stimulated Th1 cells from undergoing exhaustion. Chodisetti SB, Gowthaman U, Rai PK, Vidyarthi A, Khan N, Agrewala JN.
J Biol Chem. 289:2014:17515-28 [IF: 5.6]. Caerulomycin A enhances the TGF-β-Smad3 signalling by suppressing IFN-γ-STAT1 signalling to expand Tregs. Gurram RK, Kujur W, Maurya SK, Agrewala JN.
J Infect Dis. 209:2014:1436-45 [IF: 6.3]. Latency Associated Protein Acr1 Impairs Dendritic Cells Maturation and Functionality: A Possible Mechanism of Immune Evasion by Mycobacterium tuberculosis. Siddiqui KF, Amir M, Gurram RK, Khan N, Arora A, K Rajagopal, Agrewala JN.
Crit Rev Microbiol. 40:2014:273-280. [IF: 8.192]. Friendly Pathogens: Prevent or Provoke Autoimmunity. Sathybama S, Khan N, Agrewala JN.
J Biol Chem. 288: 2013: 29987-99 [IF: 6.8]. Truncated hemoglobin, HbN, is post-translationally modified in Mycobacterium tuberculosis and modulates host-pathogen interactions during intracellular infection. Arya S, Sethi D, Singh S, Hade MD, Singh V, Raju P, Chodisetti SB, Verma D, Varshney GC, Agrewala JN, Dikshit KL.
Trends Mol Medicine. 18:2012:607-14. [IF: 11.05]. Lipidated promiscuous peptides vaccine for tuberculosis endemic regions. Gowthaman U, Rai PK, Khan N, Jackson D, Agrewala JN.
PLoS Pathogens. 2012 Jun; 8(6):e1002676. [IF: 9.23]. Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici. Khan N, Gowthaman U, Pahari S, Agrewala JN.
J Immunol. 188:2012:5593. [IF: 5.8]. M. tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARγ and TR4 for survival. Mahajan S, Dkhar KH, Chandra V, Dave S, Nanduri R, Janmeja AK, Agrewala JN, Gupta.
J Infect Dis. 204:2011:1328-38. [IF: 6.3]. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against M. tuberculosis by evoking enduring memory T cells response. Gowthaman U, Singh V, Zeng W, Jain S, Siddiqui KF, Chodisetti SB, Gurram RK, Parihar P, Gupta P, Gupta UD, Jackson DC, Agrewala JN.
Crit Rev Microbiol. 37:2011:349-57 [IF: 8.192]. Understanding the biology of 16 kDa antigen of Mycobacterium tuberculosis: scope in diagnosis, vaccine design and therapy. Siddiqui KF, Amir M, Agrewala JN.
J Infect Dis. 202:2010:480-9 [IF: 6.3]. Singh V, Gowthaman U, Jain S, Parihar P, Banskar S, Gupta P, Gupta UD, Agrewala JN. Co-administration of IL-7 and IL-15 with BCG mount enduring T cell memory response against M. tuberculosis
J Proteome Res. 6:2007:4770-6. (Impact factor: 7.1). Gowthaman U, Agrewala JN. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion.
J Biol Chem. 282:2007:6106-15. (Impact factor: 7.6). Agrewala JN, Brown DM, Lepak NM, Duso D, Huston G, Swain SL. Unique ability of activated CD4+ T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation.
Immunol Rev. 211:2006:8-22. (Impact factor: 10.76). Swain SL, Agrewala JN, Brown D, Gibbs DJ, Golech S, Huston G, Jones S, Kamperschroer C, Lee WH, McKinstry K, Roman E, Strutt T, Weng NP. CD4 memory: generation and multi-faceted roles for CD4 T Cells in protective immunity to influenza.
J Infect Dis. 190:2004:107-14. (Impact factor: 7.94). Sharma N, Agrewala JN. Potent role of the vaccines prepared from macrophages infected with live bacteria in protection against M. tuberculosis and S. typhimurium infections.
J Biol Chem. 277:2002:7766-75. (Impact factor: 7.6). Suvas S, Singh, V, Sahdev, S, Vohra, H, Agrewala, JN. Distinct Role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma.
Eur J Immunol. 29:1999:1753-61. (Impact factor: 6.01). Agrewala JN, Wilkinson RJ. Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kD α-crystalline antigen of Mycobacterium tuberculosis.
J Immunol. 160:1998:1067-77. (Impact factor: 7.16). Agrewala JN, Suvas S, Verma RK, Mishra GC. Differential effect of anti-B7-1 and anti-M150 antibodies in restricting the delivery of costimulatory signals from B cells and macrophages.
J Immunol. 153:1994:1613-25. (Impact factor: 7.4). Vijayakrishnan L, Kumar V, Agrewala JN, Mishra GC, Rao KVS. Antigen-specific early primary humoral responses modulate Immunodominance of B cell epitopes.
Eur J Immunol. 24:1994:2092-7. (Impact factor: 6.9). Agrewala JN, Vinay DS, Joshi A, Mishra GC. A 150-kDa molecule of murine macrophage membrane stimulates interleukin-2 and interferon-g production and proliferation of ovalbumin-specific CD4+ T cells.
Visit for complete list of publications: https://scholar.google.co.in/citations?user=1ho6AokAAAAJ&hl=en
Agrewala JN, Sharma N. Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infectious diseases and the vaccine produced by the process [2004]. United States Patent No. 6,783,765, South Africa Patent No. 2002/2511, Russian and Bangladesh Patent No. 1003852.
Singla AK, Agrewala JN, Vohra RM, Jolly RS. Caerulomycin A as an immunosuppressive agent. United States Patent No. 8,114,895, China (CN101287465), PCT (WO2007031832), on February 14, 2012.
Agrewala JN, Gowthaman U, Jackson D, Zeng W. Synthetic immunogen useful for generating long- lasting immunity and protection against pathogens. United States Patent No. 9340622 (2016), EPO No. 2616098].
Sarkar D, Samuel JS, Agrewala JN, SB Chodsetti. rHuEpo variants with altered in vitro and in vivo properties. Indian Patent Application No. 2403DEL2013; filing date: 17/10/2013.
Caerulomycin A as an immunosuppressive agent. Technology licensed to Nostrum Pharmaceuticals, USA. Team: JN Agrewala, RS Jolly, RM Vohra.
Mir MA, Agrewala JN. Influence of immunomodulation of CD80 and CD86 costimulatory molecules in the infectious diseases. Proc on Biotech Approach to Neuro-immunomodulation and Infectious Diseases 2008, vol. 2 Pp 413-424.
Mir MA, Agrewala JN. Dietary polyphenols in modulation of the immune system. 2007. Polyphenols and Health: New and Recent Advances. N. Vassallo [eds], Nova Science Publishers. New York.
Agrewala JN. Antigen presentation and memory. Immunotherapeutics and disease management [2005]. Proceedings of 12th Annual Symposium, Ranbaxy Science Foundation pp15-22. New Delhi, Nov 2005.
Swain SL, Agrewala JN., Brown DM. Regulation of memory CD4 T cells: Generation, localization and persistence [2002]. Lymphocyte Activation and Immune Regulation IX - Homeostasis Lymphocyte Traffic pp. 113-120. S. Gupta, E. Butcher, and W. Paul [eds], Kluwer Academic/Plenum Publishers, New York.
Ghei SK, Sengupta U, Agrewala JN., Kailash S, Gunasekharan N, Sudhakar KS, Desikan KV, Shepard CC, Shinnick T. 1996. Association of HLA antigens with leprosy, p. 273-278. In Singh, J. [eds], Current Concepts in Human Genetics. Guru Nanak Dev University, Amritsar.